Trials on veterans suggest ibogaine could provide a new treatment for PTSD
Research into the banned hallucinogen ibogaine as a treatment for PTSD and traumatic brain injury in military veterans is drawing interest, but also concern over its significant cardiac risks and history of deaths even under medical supervision. Commenters compare ibogaine with other psychedelics, antidepressants, and treatments like ECT and TMS, debating whether its intense, often dysphoric psychedelic experience is central to its therapeutic value or an unnecessary danger. Many note that veterans are a politically favored test population and worry that media and funding focus on them obscures broader PTSD populations and the risks of poorly regulated “psychedelic therapy” clinics.
Choice of ibogaine vs other psychedelics
- Several commenters question why ibogaine is chosen over alternatives like psilocybin, LSD, DMT, or Salvia divinorum, which are seen as safer or less cardiotoxic.
- Others argue ibogaine’s specific pharmacology (kappa-opioid activity, effects on serotonin/NMDA, possible neurotrophic effects) may uniquely help with PTSD and traumatic brain injury (TBI).
- There is debate over whether similar psychological effects could be achieved with cheaper or legal substances like DXM.
Safety, cardiotoxicity, and evidence quality
- Some describe ibogaine as “horribly unsafe” for the heart, requiring intensive monitoring; others say risks are manageable with proper screening and magnesium supplementation.
- Multiple deaths linked to ibogaine are noted, including ones reported as occurring in clinical contexts; another commenter counters that at least one such case involved serious provider negligence.
- A cited open-label brain-imaging study suggesting structural changes after ibogaine is criticized for lacking a control group.
Veteran focus and political framing
- Many question why trials emphasize veterans over larger PTSD populations (e.g., assault survivors). Explanations offered: easier recruitment via the VA system, better medical records, strong political support for veteran-focused research, and defense-related funding.
- Some see this as neglect of non-veteran PTSD sufferers; others say starting with a homogeneous group is scientifically cleaner.
Addiction, PTSD, and TBI mechanisms
- Longstanding use of ibogaine for opioid and alcohol addiction is discussed, with mixed anecdotal reports: from “life-changing” to no lasting benefit.
- One view reduces ibogaine to “just another opioid,” while others emphasize that treatment is typically a one-off session, not maintenance.
- There is argument over whether PTSD is fundamentally brain damage (e.g., concussion/shell shock) or a psychological trauma response; several commenters insist the standard definition does not require head injury.
Comparison to other treatments
- Some ask why established interventions like ECT or TMS get less attention despite strong evidence for severe depression, while others highlight ECT’s risks, cognitive side effects, and traumatic experiences.
- Comparisons are drawn to SSRIs and other mental health tradeoffs: partial relief with side effects may still be worthwhile.
Therapeutic ecosystem and commercialization
- Concerns are raised about “therapeutic cults” and wellness pseudoscience around illegal psychedelics, underscoring the need for careful, regulated clinical trials.
- Others complain about regulatory “red tape,” while some support strict oversight given ibogaine’s risk profile.